hVIVO plc (HVO.L) LSE

10.10

-0.005(-0.05%)

Updated at September 08 01:07PM

Currency In GBp

hVIVO plc

Address

21 Plumbers Row

London, E1 1EQ

United Kingdom of Great Britain and Northern Ireland

Phone

44 20 7756 1300

Sector

Healthcare

Industry

Biotechnology

Employees

301

First IPO Date

December 14, 2012

Key Executives

NameTitlePayYear Born
Dr. Yamin Mohammed Khan Ph.D.Chief Executive Officer & Director697,0001969
Mr. Stephen Mark PinkertonChief Financial Officer & Executive Director349,0001963
Ms. Teja Marathe-SarvadikarHead of QA0N/A
Mr. Andrew CatchpoleChief Scientific Officer0N/A

Description

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers. The Disease in Motion platform has various potential applications across a range of end users, including big technology, wearables, pharma, and biotech companies. Further, the company provides pre­clinical and early clinical research services; sales and marketing services; and biometry, data management, and statistics to its various European pharmaceutical clients, as well as drug development consultancy and services, including CMC (chemistry, manufacturing, and controls), and PK and medical writing to a range of European clients. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.